Entero-CR contains 15 of the most well-researched and clinically validated classes of probiotics, two of which have been clinically proven to reduce DNA damage in the colon.
Research shows that adherence to screening guidelines is only 50% effective in reducing the risk of developing CRC-related death (3). A multifaceted preventive approach is key and there is growing scientific evidence that probiotics could be an integral part of an optimal prevention strategy.
CRC is the third most common cancer in the US with a ~50% projected increase by 2030.
Learn morePathogenic bacteria residing in our gut produce tumorigenic genotoxins.
Learn moreTwo probiotic strains in Entero-CR are clinically proven to reduce DNA damage, a biomarker for colon cancer risk.
Learn moreColorectal cancer (CRC) is the third leading cause of cancer worldwide and the second most deadly (1).
Experts are noting a particularly worrisome rise in the incidence of CRC in people younger than 50 years old (early-onset) who are being diagnosed with later stages of the disease. (2,11)